{"id":21612,"date":"2024-04-22T09:15:00","date_gmt":"2024-04-22T01:15:00","guid":{"rendered":"https:\/\/tbenews.com\/tbe\/?p=21612"},"modified":"2024-04-19T11:23:06","modified_gmt":"2024-04-19T03:23:06","slug":"snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection","status":"publish","type":"post","link":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/","title":{"rendered":"Snapshot week 17\/2024 <br\/>No protection by recombinant non-structural protein 3 against TBE virus infection"},"content":{"rendered":"<span class=\"cb-itemprop\" itemprop=\"reviewBody\">\n<p class=\"wp-block-paragraph\">Kubinski et al.<br>Immunity to tick-borne encephalitis virus NS3 protein induced with a recombinant modified vaccinia virus Ankara fails to afford mice protection against TBEV infection<br><em>Vaccines<\/em>. 2024;12(1):105. doi:10.3390\/vaccines12010105<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current TBE vaccines are based on chemically inactivated virions. Their protection capacity is mainly based on the immunogenicity of glycoprotein E.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It has been shown that among the non-structural proteins (NS), NS1 can also contribute to protection in mice against lethal challenge with TBE virus, e.g. when recombinantly expressed by modified vaccinia virus Ankara (MVA) or when fused in-frame to the N-terminus of the neuraminidase gene of neuraminidase-deficient influenza virus (<a href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-38-2023-partial-protection-against-lethal-infection-of-mice-by-recombinant-nonstructural-protein-1-of-tbe-virus\/\">Snapshot week 38\/2023<\/a>).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Among the NS proteins, NS3 plays a central role in the replication cycle of flaviviruses and also in polyprotein processing, and it has triphosphatase activity. It has been shown that NS3 can induce T-cell responses. Therefore, it was tested if NS3 can have a protective potential when expressed by MVA and used for immunization of mice (MVA-NS3).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mice immunized twice with MVA-NS3 developed non-neutralizing TBE specific antibodies and a specific T-cell response (in contrast to empty MVA vector). In contrast to mice vaccinated with a commercial TBE vaccine (FSME Immun), mice vaccinated with MVA-NS3 were not protected against a challenge with TBE virus strain Neud\u00f6rfl and developed severe clinical signs. TBE virus replicated in the brain and spleen and showed macroscopical lesions in the gastrointestinal tract.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The authors concluded that NS3 is not a promising candidate of next-generation TBE vaccines.<\/p>\n<\/span>","protected":false},"excerpt":{"rendered":"<p>Kubinski et al.Immunity to tick-borne encephalitis virus NS3 protein induced with a recombinant modified vaccinia virus Ankara fails to afford mice protection against TBEV infectionVaccines. 2024;12(1):105. doi:10.3390\/vaccines12010105 Current TBE vaccines are based on chemically inactivated virions. Their protection capacity is mainly based on the immunogenicity of glycoprotein E. It has been shown that among the non-structural proteins (NS), NS1 can also contribute to protection in mice against lethal challenge with TBE virus, e.g. when recombinantly expressed by modified vaccinia virus Ankara (MVA) or when fused in-frame to the N-terminus of the neuraminidase gene of neuraminidase-deficient influenza virus (Snapshot week 38\/2023). Among the NS proteins, NS3 plays a central role in the replication cycle of flaviviruses and also in polyprotein processing, and it has triphosphatase activity. It has been shown that NS3 can induce T-cell responses. Therefore, it was tested if NS3 can have a protective potential when expressed by MVA and used for immunization of mice (MVA-NS3). Mice immunized twice with MVA-NS3 developed non-neutralizing TBE specific antibodies and a specific T-cell response (in contrast to empty MVA vector). In contrast to mice vaccinated with a commercial TBE vaccine (FSME Immun), mice vaccinated with MVA-NS3 were not protected against a challenge with TBE virus strain Neud\u00f6rfl and developed severe clinical signs. TBE virus replicated in the brain and spleen and showed macroscopical lesions in the gastrointestinal tract. The authors concluded that NS3 is not a promising candidate of next-generation TBE vaccines.<\/p>\n","protected":false},"author":1409,"featured_media":20968,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[18],"tags":[324,1113,1023,1112,1052],"coauthors":[652],"class_list":["post-21612","post","type-post","status-publish","format-standard","has-post-thumbnail","category-snapshot","tag-antibodies","tag-challenge-studies","tag-modified-vaccinia-virus-ankara","tag-non-structural-protein-3","tag-t-cell-response-2"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Snapshot week 17\/2024 No protection by recombinant non-structural protein 3 against TBE virus infection - TBE Book<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snapshot week 17\/2024 No protection by recombinant non-structural protein 3 against TBE virus infection - TBE Book\" \/>\n<meta property=\"og:description\" content=\"Kubinski et al.Immunity to tick-borne encephalitis virus NS3 protein induced with a recombinant modified vaccinia virus Ankara fails to afford mice protection against TBEV infectionVaccines. 2024;12(1):105. doi:10.3390\/vaccines12010105 Current TBE vaccines are based on chemically inactivated virions. Their protection capacity is mainly based on the immunogenicity of glycoprotein E. It has been shown that among the non-structural proteins (NS), NS1 can also contribute to protection in mice against lethal challenge with TBE virus, e.g. when recombinantly expressed by modified vaccinia virus Ankara (MVA) or when fused in-frame to the N-terminus of the neuraminidase gene of neuraminidase-deficient influenza virus (Snapshot week 38\/2023). Among the NS proteins, NS3 plays a central role in the replication cycle of flaviviruses and also in polyprotein processing, and it has triphosphatase activity. It has been shown that NS3 can induce T-cell responses. Therefore, it was tested if NS3 can have a protective potential when expressed by MVA and used for immunization of mice (MVA-NS3). Mice immunized twice with MVA-NS3 developed non-neutralizing TBE specific antibodies and a specific T-cell response (in contrast to empty MVA vector). In contrast to mice vaccinated with a commercial TBE vaccine (FSME Immun), mice vaccinated with MVA-NS3 were not protected against a challenge with TBE virus strain Neud\u00f6rfl and developed severe clinical signs. TBE virus replicated in the brain and spleen and showed macroscopical lesions in the gastrointestinal tract. The authors concluded that NS3 is not a promising candidate of next-generation TBE vaccines.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/\" \/>\n<meta property=\"og:site_name\" content=\"TBE Book\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-22T01:15:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"IT\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"IT\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\\\/\"},\"author\":{\"name\":\"IT\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/6dd4b733e0a9724f047e3b700d0995f6\"},\"headline\":\"Snapshot week 17\\\/2024 No protection by recombinant non-structural protein 3 against TBE virus infection\",\"datePublished\":\"2024-04-22T01:15:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\\\/\"},\"wordCount\":255,\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/TBE-Snapshots.jpg\",\"keywords\":[\"antibodies\",\"challenge studies\",\"Modified Vaccinia virus Ankara\",\"Non-structural protein 3\",\"T-cell response\"],\"articleSection\":[\"Snapshot\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\\\/\",\"name\":\"Snapshot week 17\\\/2024 No protection by recombinant non-structural protein 3 against TBE virus infection - TBE Book\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/TBE-Snapshots.jpg\",\"datePublished\":\"2024-04-22T01:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/TBE-Snapshots.jpg\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/TBE-Snapshots.jpg\",\"width\":1180,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Snapshot week 17\\\/2024 No protection by recombinant non-structural protein 3 against TBE virus infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"name\":\"The TBE Book\",\"description\":\"Tick-borne Encephalitis (TBE)\",\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\",\"name\":\"Global Health Press\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"width\":1000,\"height\":715,\"caption\":\"Global Health Press\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/6dd4b733e0a9724f047e3b700d0995f6\",\"name\":\"IT\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4df267d44fb154b70d642e56823f4ab2f6911852f88987e2bd5be087f7b3fa95?s=96&d=mm&r=g49b710224e606e5d7fddba562c9de771\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4df267d44fb154b70d642e56823f4ab2f6911852f88987e2bd5be087f7b3fa95?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4df267d44fb154b70d642e56823f4ab2f6911852f88987e2bd5be087f7b3fa95?s=96&d=mm&r=g\",\"caption\":\"IT\"},\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/author\\\/brianong\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Snapshot week 17\/2024 No protection by recombinant non-structural protein 3 against TBE virus infection - TBE Book","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/","og_locale":"en_US","og_type":"article","og_title":"Snapshot week 17\/2024 No protection by recombinant non-structural protein 3 against TBE virus infection - TBE Book","og_description":"Kubinski et al.Immunity to tick-borne encephalitis virus NS3 protein induced with a recombinant modified vaccinia virus Ankara fails to afford mice protection against TBEV infectionVaccines. 2024;12(1):105. doi:10.3390\/vaccines12010105 Current TBE vaccines are based on chemically inactivated virions. Their protection capacity is mainly based on the immunogenicity of glycoprotein E. It has been shown that among the non-structural proteins (NS), NS1 can also contribute to protection in mice against lethal challenge with TBE virus, e.g. when recombinantly expressed by modified vaccinia virus Ankara (MVA) or when fused in-frame to the N-terminus of the neuraminidase gene of neuraminidase-deficient influenza virus (Snapshot week 38\/2023). Among the NS proteins, NS3 plays a central role in the replication cycle of flaviviruses and also in polyprotein processing, and it has triphosphatase activity. It has been shown that NS3 can induce T-cell responses. Therefore, it was tested if NS3 can have a protective potential when expressed by MVA and used for immunization of mice (MVA-NS3). Mice immunized twice with MVA-NS3 developed non-neutralizing TBE specific antibodies and a specific T-cell response (in contrast to empty MVA vector). In contrast to mice vaccinated with a commercial TBE vaccine (FSME Immun), mice vaccinated with MVA-NS3 were not protected against a challenge with TBE virus strain Neud\u00f6rfl and developed severe clinical signs. TBE virus replicated in the brain and spleen and showed macroscopical lesions in the gastrointestinal tract. The authors concluded that NS3 is not a promising candidate of next-generation TBE vaccines.","og_url":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/","og_site_name":"TBE Book","article_published_time":"2024-04-22T01:15:00+00:00","og_image":[{"width":1180,"height":250,"url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","type":"image\/jpeg"}],"author":"IT","twitter_card":"summary_large_image","twitter_misc":{"Written by":"IT","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/#article","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/"},"author":{"name":"IT","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/6dd4b733e0a9724f047e3b700d0995f6"},"headline":"Snapshot week 17\/2024 No protection by recombinant non-structural protein 3 against TBE virus infection","datePublished":"2024-04-22T01:15:00+00:00","mainEntityOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/"},"wordCount":255,"publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","keywords":["antibodies","challenge studies","Modified Vaccinia virus Ankara","Non-structural protein 3","T-cell response"],"articleSection":["Snapshot"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/","url":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/","name":"Snapshot week 17\/2024 No protection by recombinant non-structural protein 3 against TBE virus infection - TBE Book","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/#primaryimage"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","datePublished":"2024-04-22T01:15:00+00:00","breadcrumb":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/#primaryimage","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2023\/12\/TBE-Snapshots.jpg","width":1180,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-17-2024-no-protection-by-recombinant-non-structural-protein-3-against-tbe-virus-infection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tbenews.com\/tbe\/"},{"@type":"ListItem","position":2,"name":"Snapshot week 17\/2024 No protection by recombinant non-structural protein 3 against TBE virus infection"}]},{"@type":"WebSite","@id":"https:\/\/tbenews.com\/tbe\/#website","url":"https:\/\/tbenews.com\/tbe\/","name":"The TBE Book","description":"Tick-borne Encephalitis (TBE)","publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tbenews.com\/tbe\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tbenews.com\/tbe\/#organization","name":"Global Health Press","url":"https:\/\/tbenews.com\/tbe\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","width":1000,"height":715,"caption":"Global Health Press"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/6dd4b733e0a9724f047e3b700d0995f6","name":"IT","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/4df267d44fb154b70d642e56823f4ab2f6911852f88987e2bd5be087f7b3fa95?s=96&d=mm&r=g49b710224e606e5d7fddba562c9de771","url":"https:\/\/secure.gravatar.com\/avatar\/4df267d44fb154b70d642e56823f4ab2f6911852f88987e2bd5be087f7b3fa95?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4df267d44fb154b70d642e56823f4ab2f6911852f88987e2bd5be087f7b3fa95?s=96&d=mm&r=g","caption":"IT"},"url":"https:\/\/tbenews.com\/tbe\/author\/brianong\/"}]}},"_links":{"self":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/21612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/users\/1409"}],"replies":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/comments?post=21612"}],"version-history":[{"count":1,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/21612\/revisions"}],"predecessor-version":[{"id":21613,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/21612\/revisions\/21613"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media\/20968"}],"wp:attachment":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media?parent=21612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/categories?post=21612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/tags?post=21612"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/coauthors?post=21612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}